Objective:To observe the effect of irbesartan hydrochloride on endothelial function, hemodynamics and inflammatory response in patients with essential hypertension.Method:A total of 100 patients with essential hyperte...Objective:To observe the effect of irbesartan hydrochloride on endothelial function, hemodynamics and inflammatory response in patients with essential hypertension.Method:A total of 100 patients with essential hypertension admitted from May 2015 to August 2017 in our hospital were divided into observation group (50 cases) and control group (50 cases) according to random number table. The control group was treated with routine treatment, and the observation group was treated with erbesartan hydrochlorothiazide on the basis of routine treatment in the control group. The changes of vascular endothelial function, hemodynamics and inflammatory factors in the two groups were compared.Results: Before treatment, there was no significant difference in vWF, EDD and NMD levels, hemodynamics level and CRP, ICAM-1 and MCP-1 levels. After treatment, the vWF level in the observation group was significantly decreased and the EDD level was significantly increased;while the level of NMD was not significantly changed. After treatment, the level of vWF in the control group was significantly decreased;but there was no significant change in EDD and NMD level. After treatment, vWF level (144.94±16.21)% in the observation group was significantly lower than that in the control group;EDD level (6.81±0.74)% was significantly higher than that in the control group. After treatment, the levels of LBV, HBV and PV in the observation group were significantly lower than those before treatment, while the levels of LBV, HBV and PV in the control group were not significantly different from those before treatment. After treatment, LBV level (13.34±1.41) m.pas, HBV level (5.13±1.34) m.pas and PV level (1.65±0.34) m.pas in the observation group were significantly lower than those in the control group. After treatment, the levels of CRP, ICAM-1 and MCP-1 in both groups were significantly lower than those before treatment. After treatment, the level of CRP (1.71±0.81) mg/L, ICAM-1 level (330.82±68.51) ng/mL and MCP-1 level (3.02±1.06) g/L in the observation group were significantly lower than those in the control group.Conclusion: Irbesartan hydrochlorothiazide treatment of hypertension can play a significant role in the improvement of vascular endothelial function and hemorheology in patients, and can significantly reduce the level of inflammatory response in the body, worthy of clinical application.展开更多
目的:探讨甲磺酸多沙唑嗪片联合厄贝沙坦氢氯噻嗪片治疗高血压患者的临床效果。方法:回顾性选取2021年1月—2023年9月泉州市光前医院收治的216例高血压患者作为研究对象,根据治疗方案不同将患者分为对照组与研究组,各108例。单一厄贝沙...目的:探讨甲磺酸多沙唑嗪片联合厄贝沙坦氢氯噻嗪片治疗高血压患者的临床效果。方法:回顾性选取2021年1月—2023年9月泉州市光前医院收治的216例高血压患者作为研究对象,根据治疗方案不同将患者分为对照组与研究组,各108例。单一厄贝沙坦氢氯噻嗪片治疗的设为对照组,甲磺酸多沙唑嗪片联合厄贝沙坦氢氯噻嗪片治疗的设为研究组。比较两组临床疗效、治疗前后血压变异性、血脂、血清细胞因子及不良反应。结果:研究组临床总有效率为98.15%,高于对照组的91.67%,差异有统计学意义(P<0.05);治疗后,两组24 h动脉收缩压变异性(24 h SBPV)、24 h动脉舒张压变异性(24 h DBPV)及血清C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、同型半胱氨酸(Hcy)水平降低,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组血清甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平降低,且研究组低于对照组,两组高密度脂蛋白胆固醇(HDL-C)水平升高,且研究组高于对照组,差异有统计学意义(P<0.05);研究组不良反应率为8.33%,与对照组的6.48%比较,差异无统计学意义(P>0.05)。结论:甲磺酸多沙唑嗪片联合厄贝沙坦氢氯噻嗪片治疗高血压,可调节血压变异性,降低血脂、血清细胞因子水平,疗效显著,且安全性高。展开更多
文摘Objective:To observe the effect of irbesartan hydrochloride on endothelial function, hemodynamics and inflammatory response in patients with essential hypertension.Method:A total of 100 patients with essential hypertension admitted from May 2015 to August 2017 in our hospital were divided into observation group (50 cases) and control group (50 cases) according to random number table. The control group was treated with routine treatment, and the observation group was treated with erbesartan hydrochlorothiazide on the basis of routine treatment in the control group. The changes of vascular endothelial function, hemodynamics and inflammatory factors in the two groups were compared.Results: Before treatment, there was no significant difference in vWF, EDD and NMD levels, hemodynamics level and CRP, ICAM-1 and MCP-1 levels. After treatment, the vWF level in the observation group was significantly decreased and the EDD level was significantly increased;while the level of NMD was not significantly changed. After treatment, the level of vWF in the control group was significantly decreased;but there was no significant change in EDD and NMD level. After treatment, vWF level (144.94±16.21)% in the observation group was significantly lower than that in the control group;EDD level (6.81±0.74)% was significantly higher than that in the control group. After treatment, the levels of LBV, HBV and PV in the observation group were significantly lower than those before treatment, while the levels of LBV, HBV and PV in the control group were not significantly different from those before treatment. After treatment, LBV level (13.34±1.41) m.pas, HBV level (5.13±1.34) m.pas and PV level (1.65±0.34) m.pas in the observation group were significantly lower than those in the control group. After treatment, the levels of CRP, ICAM-1 and MCP-1 in both groups were significantly lower than those before treatment. After treatment, the level of CRP (1.71±0.81) mg/L, ICAM-1 level (330.82±68.51) ng/mL and MCP-1 level (3.02±1.06) g/L in the observation group were significantly lower than those in the control group.Conclusion: Irbesartan hydrochlorothiazide treatment of hypertension can play a significant role in the improvement of vascular endothelial function and hemorheology in patients, and can significantly reduce the level of inflammatory response in the body, worthy of clinical application.
文摘目的:探讨甲磺酸多沙唑嗪片联合厄贝沙坦氢氯噻嗪片治疗高血压患者的临床效果。方法:回顾性选取2021年1月—2023年9月泉州市光前医院收治的216例高血压患者作为研究对象,根据治疗方案不同将患者分为对照组与研究组,各108例。单一厄贝沙坦氢氯噻嗪片治疗的设为对照组,甲磺酸多沙唑嗪片联合厄贝沙坦氢氯噻嗪片治疗的设为研究组。比较两组临床疗效、治疗前后血压变异性、血脂、血清细胞因子及不良反应。结果:研究组临床总有效率为98.15%,高于对照组的91.67%,差异有统计学意义(P<0.05);治疗后,两组24 h动脉收缩压变异性(24 h SBPV)、24 h动脉舒张压变异性(24 h DBPV)及血清C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、同型半胱氨酸(Hcy)水平降低,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组血清甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平降低,且研究组低于对照组,两组高密度脂蛋白胆固醇(HDL-C)水平升高,且研究组高于对照组,差异有统计学意义(P<0.05);研究组不良反应率为8.33%,与对照组的6.48%比较,差异无统计学意义(P>0.05)。结论:甲磺酸多沙唑嗪片联合厄贝沙坦氢氯噻嗪片治疗高血压,可调节血压变异性,降低血脂、血清细胞因子水平,疗效显著,且安全性高。
